Context Therapeutics (NASDAQ:CNTX) Upgraded at Citizens Jmp

Context Therapeutics (NASDAQ:CNTX) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other brokerages have also recently commented on CNTX. D. Boral Capital assumed coverage on Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 price target for the company. JMP Securities started coverage on Context Therapeutics in a report on Wednesday. They set an “outperform” rating and a $4.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Stock Up 11.0 %

Shares of Context Therapeutics stock opened at $1.21 on Wednesday. The company has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.93. The firm has a market capitalization of $90.75 million, a P/E ratio of -1.33 and a beta of 2.10. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Driehaus Capital Management LLC acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth approximately $4,527,000. Great Point Partners LLC purchased a new stake in Context Therapeutics during the second quarter worth $14,876,000. Blue Owl Capital Holdings LP acquired a new stake in Context Therapeutics during the second quarter valued at $10,348,000. State Street Corp grew its position in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after buying an additional 19,800 shares during the period. Finally, Nantahala Capital Management LLC purchased a new position in Context Therapeutics in the second quarter valued at $3,881,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.